急性痛风性关节炎的药物治疗及选择

被引：63

作者：

于一云 ^{[1
,2
]}

薛愉 ^{[1
,2
]}

朱小霞 ^{[1
,2
]}

邹和建 ^{[1
,2
]}

机构：

[1] 复旦大学附属华山医院风湿科

[2] 复旦大学风湿免疫过敏性疾病研究中心

来源：

上海医药 | 2015年 / 36卷 / 11期

基金：

高等学校博士学科点专项科研基金;

关键词：

急性痛风性关节炎; 药物治疗; 生物制剂;

D O I：

暂无

中图分类号：

R589.7 [嘌呤（Purine）代谢障碍];

学科分类号：

100201 [内科学];

摘要：

痛风是由嘌呤代谢障碍引起的一种代谢性疾病。急性痛风性关节炎是痛风的最常见首发症状,传统治疗药物包括非甾体抗炎药物、秋水仙碱和糖皮质激素。炎性细胞因子在急性痛风性关节炎的发病中起着重要作用,故能阻断炎症介质如白介素-1、肿瘤坏死因子-α等的生物制剂有望在该疾病治疗中得到广泛的应用。本文就急性痛风性关节炎的药物治疗作一概要介绍。

引用

页码：14 / 18

页数：5

共 9 条

[1]

Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients With Anakinra [J].

Ghosh, Pradipta ;

Cho, Michael ;

Rawat, Gurpreet ;

Simkin, Peter A. ;

Gardner, Gregory C. .

ARTHRITIS CARE & RESEARCH, 2013, 65 (08) :1381-1384

[2]

Treatment of Chronic Gouty Arthritis: It Is Not Just About Urate-Lowering Therapy [J].

Schlesinger, Naomi .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2012, 42 (02) :155-165

[3]

Rilonacept (interleukin‐1 trap) for prevention of gout flares during initiation of uric acid–lowering therapy: Results from a phase III randomized; double‐blind; placebo‐controlled; confirmatory efficacy study.[J].H. Ralph Schumacher;Robert R. Evans;Kenneth G. Saag;James Clower;William Jennings;Steven P. Weinstein;George D. Yancopoulos;Jian Wang;Robert Terkeltaub.Arthritis Care Res.2012, 10

[4]

2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis [J].

Khanna, Dinesh ;

Khanna, Puja P. ;

Fitzgerald, John D. ;

Singh, Manjit K. ;

Bae, Sangmee ;

Neogi, Tuhina ;

Pillinger, Michael H. ;

Merill, Joan ;

Lee, Susan ;

Prakash, Shraddha ;

Kaldas, Marian ;

Gogia, Maneesh ;

Perez-Ruiz, Fernando ;

Taylor, Will ;

Liote, Frederic ;

Choi, Hyon ;

Singh, Jasvinder A. ;

Dalbeth, Nicola ;

Kaplan, Sanford ;

Niyyar, Vandana ;

Jones, Danielle ;

Yarows, Steven A. ;

Roessler, Blake ;

Kerr, Gail ;

King, Charles ;

Levy, Gerald ;

Furst, Daniel E. ;

Edwards, N. Lawrence ;

Mandell, Brian ;

Schumacher, H. Ralph ;

Robbins, Mark ;

Wenger, Neil ;

Terkeltaub, Robert .

ARTHRITIS CARE & RESEARCH, 2012, 64 (10) :1447-1461

[5]

Prevalence of Contraindications and Prescription of Pharmacologic Therapies for Gout [J].

Keenan, Robert T. ;

O'Brien, William R. ;

Lee, Kristen H. ;

Crittenden, Daria B. ;

Fisher, Mark C. ;

Goldfarb, David S. ;

Krasnokutsky, Svetlana ;

Oh, Cheongeun ;

Pillinger, Michael H. .

AMERICAN JOURNAL OF MEDICINE, 2011, 124 (02) :155-163

[6]

Effect of Prophylaxis on Gout Flares After the Initiation of Urate-Lowering Therapy: Analysis of Data From Three Phase III Trials [J].

Wortmann, Robert L. ;

MacDonald, Patricia A. ;

Hunt, Barbara ;

Jackson, Robert L. .

CLINICAL THERAPEUTICS, 2010, 32 (14) :2386-2397

[7]

Anakinra's Efficacy is Variable in Refractory Gout: Report of Ten Cases [J].

Chen, Kun ;

Fields, Theodore ;

Mancuso, Carol A. ;

Bass, Anne R. ;

Vasanth, Lisa .

SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (03) :210-214

[8]

Canakinumab for the Treatment of Acute Flares in Difficult-to-Treat Gouty Arthritis Results of a Multicenter, Phase II, Dose-Ranging Study [J].

So, Alexander ;

De Meulemeester, Marc ;

Pikhlak, Andrey ;

Yucel, A. Eftal ;

Richard, Dominik ;

Murphy, Valda ;

Arulmani, Udayasankar ;

Sallstig, Peter ;

Schlesinger, Naomi .

ARTHRITIS AND RHEUMATISM, 2010, 62 (10) :3064-3076

[9]

TARGETING TUMOUR NECROSIS FACTOR ALPHA.[J].Jeffrey R. LaDuca;Anthony A. Gaspari.Dermatologic Clinics.2001, 4

← 1 →